Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-derived MSCs plus everolimus to enable tacrolimus withdrawal after kidney transplantation
NL-OMON38620Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2014
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus, autologous bone-marrow mesenchymal stem cells and tacrolimus in kidney transplant immunosuppression and Transplant Nephropathy (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Change in allograft fibrosis. Started Apr 2014; status: active, not recruiting.
02
Drugs
everolimusautologous bone-marrow mesenchymal stem cellstacrolimus
03
Conditions
kidney transplant immunosuppressionTransplant Nephropathy
Beyond the preview
Go deeper on NL-OMON38620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38620.